Meditech snares Moses for board
Thursday, 30 May, 2002
Hyaluron drug delivery company Meditech Research (ASX:MTR) has named sought-after business analyst Bob Moses as chairman of its board.
Moses joined the board in October last year after retiring as vice-president of CSL.
His appointment to the chairman's position sees him replace acting chairman Prof Richard Fox, a Royal Melbourne Hospital oncologist who will remain on the board and continue to lead the company's clinical trail activities.
Fox said Moses would bring to the company 35 years of experience in the pharmaceutical and biotech industry.
"His commercial understanding greatly strengthens the company at a time when its technology is emerging from the laboratory and attracting the attention of multinational pharmaceutical companies," Fox said.
It has been a busy couple of weeks for Moses who last week was named a non-executive director on the board of Amrad Corporation as part of a compromise between the company and its major shareholder Circadian Technologies.
Moses is also the chairman of Circadian subsidiary Antisense Therapeutics.
Before joining CSL, Moses spent 17 years in a variety of management roles within multinational pharmaceutical house, Eli Lilly.
The appointment comes a week after the Perth-based company signed a licence agreement with the Lion's Eye Institute allowing the institute to use Meditech's patents in the development of products for the treatment and prevention of eye diseases.
The patents relate to the use of hyaluronic acid as a transporter of DNA into cells.
Also this month, the company completed Phase I trials of its anti-cancer therapy HyDox, finding the treatment was safe for patients with breast cancer, renal carcinoma, sarcoma and prostate cancer.
The trials, headed by Fox, were conducted through the Centre For Developmental Cancer Therapeutics (CDCT), a Melbourne consortium comprising The Royal Melbourne Hospital, The Walter & Eliza Hall Institute, The Peter MacCallum Cancer Institute, The Ludwig Institute, The Austin and Repatriation Medical Centre, and Western Hospital.
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
The microbiome helps to fight melanoma
Molecules produced by gut bacteria upon digestion of dietary fibre can improve the function of...
Heart implant brings hope to refractory angina patients
The coronary sinus reducer is understood to redistribute blood flow within the wall of the heart,...
